DSP-2230
Investigational analgesic drug
 | |
| Clinical data | |
|---|---|
| Routes of administration | By mouth |
| Identifiers | |
| |
| CAS Number |
|
| UNII |
|
| ChEMBL |
|
| Chemical and physical data | |
| Formula | C20H20F3N5O2 |
| Molar mass | 419.408 g·mol−1 |
| 3D model (JSmol) |
|
| |
InChI
| |
DSP-2230 is a selective small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker which is under development by Dainippon Sumitomo Pharma for the treatment of neuropathic pain.[1][2] As of June 2014, it is in phase I/phase II clinical trials.[1][2]
See also
References
- ^ a b Martz L (2014). "Nav-i-gating antibodies for pain". Science-Business EXchange. 7 (23): 662. doi:10.1038/scibx.2014.662. ISSN 1945-3477.
- ^ a b Bagal SK, Chapman ML, Marron BE, Prime R, Storer RI, Swain NA (August 2014). "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters. 24 (16): 3690–9. doi:10.1016/j.bmcl.2014.06.038. PMID 25060923.
External links
- "DSP-2230". AdisInsight. Springer Nature Switzerland AG.
- v
- t
- e
modulators
| Calcium blockers |
|
|---|---|
| Sodium blockers |
|
| Potassium openers |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This analgesic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
